For the Inventor, By the Inventor

Enter assignee name

Ose Immunotherapeutics

USPTO Granted Patents = 30

CIPO Patents = 4

EPO Patents = 20

Trademarks = 12

Forward Citations = 39

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Nicolas Poirier (23 out of 24 patents)

Caroline Mary (20 out of 22 patents)

Bernard Vanhove (18 out of 22 patents)

4. Vanessa Gauttier (8 out of 8 patents)

5. Virginie Thepenier (7 out of 7 patents)

6. Sabrina Pengam (6 out of 6 patents)

7. Elise Chiffoleau (3 out of 3 patents)

8. Dominique Costantini (3 out of 11 patents)

9. Géraldine Teppaz (2 out of 2 patents)

10. Aurore Morello (2 out of 2 patents)

11. Jean-Pascal Conduzorgues (2 out of 3 patents)

12. Flora Coulon (2 out of 2 patents)

13. José Cohen (1 out of 2 patents)

14. Prasad S Adusumilli (1 out of 8 patents)

15. Jean-Paul Soulillou (1 out of 6 patents)

Core Competencies:

Chimeric Antigen Receptors

CD127

Anti-PD-1 Antibodies

SIRPa Antibodies

T-Cell Response

Cancer Treatment

Humanized Antibodies

Peptide Delivery

Tumor Vaccine

Inflammatory Bowel Disease

Polypeptides

Therapeutic Applications

30 patents: Sort by Forward Citations

1. 12697388 - CHIMERIC ANTIGEN RECEPTORS TARGETING CD127 AND USE THEREOF (2026-08-04),

2. 12534533 - Anti-Chemokine Like Receptor 1 Humanized Antibodies and Their Therapeutic Applications (2026-01-27),

3. 12448454 - Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof (2025-10-21),

4. 12371502 - Antibodies directed against CD127 (2025-07-29),

5. 12331118 - Humanized anti-human-PD-1 antibody and methods of using them for cancer treatment (2025-06-17),

6. 12331115 - Uses of anti-SIRPg antibodies (2025-06-17),

7. 12258577 - Method effector cells using anti-CD127 antibodies for applications in cell therapy (2025-03-25),

8. 12252546 - Anti-SIRPa antibodies and their therapeutic applications (2025-03-18),

9. 12091464 - Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1) (2024-09-17),

10. 12077820 - Biomarkers for assessing the response status for treatment of Inflammatory condition or disease affecting the digestive tract such as inflammatory bowel disease in human patients (2024-09-03),

11. 11981713 - Method for manufacturing a stable emulsion for peptide delivery (2024-05-14),

12. 11926671 - Antibodies and polypeptides directed against CD127 (2024-03-12),

13. 11884723 - Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies (2024-01-30),

14. 11713356 - Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer (2023-08-01),

15. 11696936 - Treatment of cancer (2023-07-11),

Company Overview

Ose Immunotherapeutics is a biotechnology company based in Nantes, France, focused on developing innovative immunotherapies for the treatment of cancer and autoimmune diseases. The company specializes in harnessing the power of the immune system to create targeted therapies that enhance patient outcomes. With a strong emphasis on research and development, Ose Immunotherapeutics aims to advance its proprietary technologies and clinical programs, contributing to the evolving landscape of immunotherapy and personalized medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

30 Patents

#3 in Nantes

#725 in France

#21,853 in the World

Ose Immunotherapeutics

Forward Citations = 39

24 inventors:

Nicolas Poirier (23 out of 24 patents)

Caroline Mary (20 out of 22 patents)

Bernard Vanhove (18 out of 22 patents)

4. Vanessa Gauttier (8 out of 8 patents)

5. Virginie Thepenier (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ose Immunotherapeutics. Retrieved from https://idiyas.com/company/ose-immunotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Please report any incorrect information to [email protected]

Loading…